List of the most relevant genes of the IFN and IRDS signatures overexpressed by resident BM cells from patients with metastatic (I_BM) and localized (NI_BM) neuroblastoma.
Neuroblastoma (NB) is a pediatric tumor that arises from peripheral nervous system. The clinical presentation of NB is highly heterogeneous, ranging from asymptomatic tumor masses requiring little, if any, treatment to metastatic disease requiring intensive multimodal therapies (see  for review). Also the outcome of NB patients is highly variable. The 5-years overall survival ranges from 98-100% for stage 1 infants without
At diagnosis, about 50% of cases present metastatic spread that mainly involves vascularized tissues, such as bone marrow (BM) and bone. According to the International Neuroblastoma Staging System (INSS ), patients with metastatic disease are categorized as stage 4, whereas in the absence of metastatic spread patients are categorized as stage 1, 2 and 3, depending on the extent of the primary tumor (within or across the midline), the involvement of ipsilateral or controlateral lymph nodes, and the surgical possibility of resection. Recently, the INSS has been replaced by the International Neuroblastoma Risk Group-Stage System (INRG-SS) based on image-defined surgical risk . According to the INRG-SS criteria, patients with metastatic spread have stage M disease, while patients with localized disease have stage L1 or L2, depending on the level of surgical risk.
2. Role of bone marrow infiltration in staging of NB patients
Since the spread of tumor cells to the BM is a grim prognostic indicator for patients with NB, the search for BM infiltration is of utmost importance for both staging and therapeutic purposes. According to the INSS, presence of metastases is assessed by appropriate imaging, including 123I-MIBG scintigraphy, and morphological examination of both BM smears and trephine biopsies . In spite of the limited sensitivity of morphological analysis, alternative methods for NB cell detection, such as flow cytometry, immunocytology (IC) and reverse transcription-polymerase chain reaction (RT-PCR) for markers selectively expressed in NB cells, are not included into the staging system. The reason for this choice depends on the good survival rate of children with localized NB , suggesting that, even if present, few circulating tumor cells are not clinically relevant. Only few patients with localized NB, in fact, relapse or die of the disease. Therefore, the introduction of more sensitive methods for the detection of BM-infiltrating NB cells may cause inappropriate overtreatment of patients with localized NB, resulting in unnecessary toxicity and long term side effects. These sensitive methods, however, are currently evaluated in ongoing clinical protocols for patients with metastatic disease for their potential prognostic value.
3. Sensitive methods for detection of neuroblastoma cells in BM samples
3.1. Flow cytometry
Total cells from BM aspirates are incubated with a monoclonal antibody (mAb) directed against a neuroblastoma specific antigen, as the disialoganglioside GD2, and with a mAb specific for the hematopoietic cells, as the pan leukocyte CD45, each one labeled with a different fluorochrome. After removal of the unbound mAbs and erythrocyte lysis, samples are analyzed in a flow cytometer. The GD2-positive CD45-negative cells, shown in Figure 1, are considered BM-infiltrating NB cells and their number relative to the total hematopoietic cells can be determined.
3.2. Immunocytochemistry (IC)
Ficoll-purified mononuclear cells from BM aspirates are spotted onto slides that are fixed and then incubated with an anti-GD2 mAb. After stain development, the stained GD2-positive cells can be counted by light microscopy, relative to a given number of total mononuclear cells. Standardized conditions for IC analysis and reporting have been developed . An example of a BM slide with GD2-positive cells is shown in Figure 2.
4. Molecular analysis (qualitative and quantitative RT-PCR)
BM aspirates from the iliac crests are stored in tubes containing RNA preservative. Total RNA is then extracted and reverse transcribed (RT). For qualitative PCR analysis, the cDNA is amplified for 35 cycles in a thermal cycler with primers specific for NB related markers, such as
For quantitative analysis (qPCR), the cDNA is amplified for 40 cycles in triplicates in a real-time thermal cycler, using primers specific for a NB related marker and for a housekeeping gene, in the presence of specific probes labeled with different fluorochromes. If a cDNA specific for the NB marker is present, at each amplification cycle the probe-specific fluorescence is released and detected by the instrument. At the end of 40 cycles, the cycle at whom the released fluorescence overcomes the threshold is used to quantitate, through an algorithm , the relative amount of the NB-specific amplified product. An example of quantitative analysis is shown in Figure 4. Standardized conditions for RT-qPCR analysis and reporting have been developed .
4.1. Sensitivity, specificity, diagnostic accuracy and prognostic values of different detection methods
The sensitivity of morphological analysis is approximately 1 NB cell out of 103-104 for smear and bone trephine biopsy, respectively . Sensitivity of flow cytometry, immunocytochemistry and molecular analysis is evaluated in spiking experiments by mixing logarithmic dilutions of a NB cell line with fixed amount of mononuclear cells from a healthy donor. Sensitivity of flow cytometry is 1 out of 104 cells , whereas that of both IC and RT-qPCR is 1 out of 106 cells [11, 12].
Specificity of flow cytometry and immunocytochemistry is assessed by negative results obtained in samples from healthy donors. For molecular analysis specificity is assessed by negative results in samples reverse transcribed without reverse transcriptase and in samples amplified without cDNAs.
4.2. Comparison of different techniques and markers
The sensitivity and specificity of different techniques and of different markers have been compared [12, 14-19]. Following the development of standardized conditions , GD2 is the marker of choice for IC analysis . GD2-IC is currently evaluated for its prognostic significance in ongoing protocols for stage 4 NB patients, both in Europe and North America.
To overcome NB tumor heterogeneity and increase sensitivity and specificity of RT-PCR analysis, different panels of various NB-specific markers have been developed thanks to the microarray technology [9, 21, 22]. To date the panels have not been compared, but each panel is currently tested for its prognostic role in ongoing therapeutic protocols for stage 4 NB patients.
5. BM infiltration in patients with localized NB detected by sensitive methods
Patients with localized NB without
Since conventional morphological methods have limited sensitivity, it has been suggested that some of the patients with localized NB could have a low number of metastatic cells that could be responsible for relapse. If such hypothesis was true, the use of sensitive methods, such as IC and RT-qPCR, may be helpful in identifying patients at risk of relapse and death. Indeed, we observed that in patients with localized NB the presence of GD2 positive cells in BM samples at diagnosis negatively associated with survival . Since this finding was based on a small sample size with a relatively short follow-up, a further study performed in a larger cohort of patients confirmed the negative impact of BM GD2-positive cell infiltration on survival of patients with localized NB . Moreover, the negative impact was demonstrated to be independent of
Peripheral blood (PB) samples can be obtained without patient’s sedation with evident advantages as compared to BM samples. Thus, we tested whether RT-qPCR analysis for NB-related markers in BM and PB samples from patients with localized NB had a prognostic impact on their survival . The expression of seven different genes, previously shown to be specific for NB cells [7, 9, 13, 14, 18, 31-35], was evaluated and compared to those of healthy subjects. A high percentage of samples resulted positive for the various NB-related markers (Figure 6). Since the patients’ cohort had a fairly good survival rate, in accordance with literature data [3, 36, 37], the positive results were likely related to low transcription levels by the PB hematopoietic cells [21, 22, 32, 38], or were due to the existence of so called dormant cells, i.e., tumor cells unable to proliferate .
In the attempt to discriminate between illegitimate transcription by hematopoietic cells and transcription by low numbers of NB cells, ROC analysis was applied to find cut-off levels able to discriminate patients with localized NB from healthy subjects. Although the use of cut-off levels for each NB-related marker in PB and BM samples increased their specificity, the percentage of positive results that did not correlate with clinical events remained high. Also a modified ROC analysis  failed to improve the prognostic value of RT-qPCR analysis for any of the tested marker. However,
In conclusion, in patients with localized NB, detection of metastatic cells in BM by means of GD2-IC analysis and detection of
6. BM infiltration in patients with metastatic disease
Presence of metastasis at diagnosis in children over 18 months of age is a powerful prognostic factor for a poor outcome [2, 3]. In order to understand the mechanisms responsible for such aggressive behavior, an extensive characterization of primary tumor cells from stage 4 NB patients has been performed. DNA abnormalities [42, 43], gene expression profiles [44-46], and non-coding RNAs expression [47, 48] have been proposed as sensitive indicators of NB tumor aggressiveness. Unfortunately, all the gene classifiers, although validated on independent patient cohorts [46, 49], did not appear to be helpful in stratifying stage 4 patients into different risk groups. Moreover, whole genome sequencing of primary NB tumors  demonstrated that no specific mutations or chromosomal alterations were present in NB tumors, suggesting that the mechanisms responsible for invasiveness and metastasis should be searched elsewhere.
6.1. Role of the BM microenvironment for NB metastatic invasion
The processes of invasion, survival and proliferation at distant sites may be mediated in part by the microenvironment. In the BM, several cell types, such as adipocytes, stromal and endothelial cells are present together with cells of all hematopoietic lineages. Each cell type may secrete factors that affect several signaling pathways leading to modifications in BM structural organization and cell function. Among these factors, the CXCL12 chemokine has been proposed to play an important role in NB invasiveness [51-53], but conflicting results have been obtained [54, 55]. Thus, we decided to compare the gene expression profiles of resident BM cells from healthy children to those of BM cells from patients with localized and metastatic NB. The results indicated that the resident BM cells from patients with either localized or metastatic NB have a different genetic signature from healthy children. However, the deregulation of transcription was more evident in the BM microenvironment of patients with metastatic stage 4 disease (Figure 8) ,
Precisely, BM samples from NB patients significantly overexpressed genes involved in the innate immune responses. In particular, all NB patients expressed an interferon (IFN) signature .
IFNs are pleiotropic cytokines involved in different biological processes , and IFN signatures have been associated with tumor progression of melanoma and colorectal cancer . Moreover IFN signatures associated with the worse prognosis of African-American patients with prostate  and breast  cancer as compared to Caucasian patients. The IFN signature includes genes involved in the defense against bacterial and viral pathogens [62, 63]. Since all NB patients showed the IFN signature it was proposed that the NB primary tumor may release, or induce the release of, soluble factors as occurring during an infection. The BM microenvironment of NB patients up-regulated also the IFN related DNA damage resistance signature (IRDS), that was shown to be associated with resistance to radiation-induced DNA damage , as summarized in Table 1.
In conclusion, children with NB have evidence of chronic inflammation, more intense in the presence of infiltrating NB cells , that may reduce anti-tumor immune responses and promote tumor progression .
Furthermore, resident BM cells from patients with NB down-regulated genes involved in cell adhesion, in erythrocyte, myeloid and platelet differentiation, and most importantly, CXCL12 expression. The CXCL12 down-regulation reached near complete silencing in patients with metastatic disease (Figure 9), likely explaining the anemia and platelet dysfunctions observed in stage 4 patients.
In conclusion, NB tumor growth at the primary site can alter the BM microenvironment, and the presence of BM-infiltrating NB cells makes these alterations only more pronounced. Therefore, the BM microenvironment is unlikely to be responsible for the presence of NB cells in the BM.
6.2. Characteristics of the BM-infiltrating NB cells
To avoid any modification or selection following
Since the proteins selectively over-expressed by the BM-infiltrating NB cells may represent novel prognostic markers and potential targets for biologically driven therapy for metastatic NB patients, we performed gene expression profiling of these cells, as compared to the cells in the primary tumors . The results of the study showed that the BM-infiltrating GD2-positive cells were enriched in CD56-positive and NB84-positive mononuclear NB cells, had the same genetic aberration as the primary tumor cells, and expressed NB-specific genes as primary tumor cells. The BM-infiltrating GD2-positive cells up-regulated several genes normally expressed by different lineages of resident BM cells. Therefore, to ascribe the expression of the proteins encoded by these genes to the metastatic NB cells, we took advantage of multiple color cytofluorimetric analysis of unprocessed BM samples from stage 4 patients. While in unprocessed BM samples from healthy individuals the GD2 expression was absent , in BM samples from stage 4 NB patients the GD2-positive cells represented about 20-30% of mononuclear cells. These latter cells never express the pan-leukocyte CD45 antigen and always co-express the NB specific markers B7H3 and CD56 [77, 78] (Figure 10), thus confirming that the GD2-positive BM-infiltrating cells were indeed metastatic NB cells. All freshly isolated GD2-positive BM-infiltrating NB cells never expressed CD133, sometime co-expressed c-KIT, CD37 and CD177, but most importantly, they always expressed both HLA-G and calprotectin, as shown in Figure 10.
The heterodimer protein calprotectin, encoded by the
The GD2-positive BM-infiltrating cells also expressed HLA-G, a monomorphic HLA class Ib molecule, whose over-expression facilitate tumor escape from host immune response in a wide variety of human cancers . Since primary NB tumors did not express HLA-G , it is conceivable that HLA-G may contribute to the high aggressiveness of BM-infiltrating NB cells throughout its immunosuppressive activity.
Presence of NB cells within the BM is the most powerful negative prognostic factor for patients with NB. Presently, sensitive methods of detection of metastatic cells have been standardized , and prospective studies are ongoing to demonstrate their relative or combined prognostic role. In the near future these methods will help stratification of stage 4 patients into different risk groups. Conversely, these sensitive methods are of limited use in patients with localized NB.
To date, information about the role of the BM microenvironment in driving infiltration by metastatic cells is few and still conflicting. However, the finding that the BM microenvironment of patients with localized disease is not so different from that of patients with metastatic disease , strongly support the hypothesis that the invasion of the BM mainly depends on the characteristics of the metastatic cells, rather than on the properties of the BM microenvironment. In this regard the findings that the BM-infiltrating NB cells expressed proteins not found in the primary tumor cells is intriguing . In fact, both calprotectin and HLA-G favor tumor escape from anti-tumor immune responses, likely contributing to the survival and proliferation of the metastatic cells in the BM. These proteins may be also responsible for the state of intense chronic inflammation observed in patients with metastatic NB . Future studies are needed to elucidate the mechanisms responsible for the acquisition of the different properties of metastatic cells as compared to primary tumor cells. However, the proteins specifically expressed by BM-infiltrating metastatic NB cells could be new prognostic markers and novel therapeutic targets for high risk NB patients.
The Authors wish to thank the parents and legal guardians that have allowed the use of their children’s samples for research studies and all the physicians and pathologists that collected and centralized the samples.
The studies were supported in part by Fondazione Italiana per la Lotta al Neuroblastoma and by Ministero della Salute.
BC is recipient of Fondazione Italiana per la Lotta al Neuroblastoma fellowship.
Recent advances in neuroblastoma. New England Journal of Medicine Maris J. M 2010 362 23 2202 2211
Neuroblastoma incidence and survival in European children (1978-1997): report from the Automated Childhood Cancer Information System project. European Journal of Cancer Spix C Pastore G Sankila R Stiller C. A Steliarova-foucher E 2006 42 13 2081 2091
The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. Journal of Clinical Oncology Cohn S. L Pearson A. D London W. B Monclair T Ambros P. F Brodeur G. M et al 2009 27 2 289 297
Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. Journal of Clinical Oncology Brodeur G. M Pritchard J Berthold F Carlsen N. L Castel V Castelberry R. P et al 1993 11 8 1466 1477
The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report. Journal of Clinical Oncology Monclair T Brodeur G. M Ambros P. F Brisse H. J Cecchetto G Holmes K et al 2009 27 2 298 303
Standardization of the immunocytochemical detection of neuroblastoma cells in bone marrow. Journal of Histochemistry and Cytochemistry Swerts K Ambros P. F Brouzes C Navarro J. M Gross N Rampling D et al 2005 53 12 1433 1440
Circulating neuroblastoma cells detected by reverse transcriptase polymerase chain reaction for tyrosine hydroxylase mRNA are an independent poor prognostic indicator in stage 4 neuroblastoma in children over 1 year. Journal of Clinical Oncology Burchill S. A Lewis I. J Abrams K. R Riley R Imeson J Pearson A. D et al 2001 19 6 1795 1801
Quantitation of marrow disease in neuroblastoma by real-time reverse transcription-PCR. Clinical Cancer Research Cheung I. Y Cheung N. K 2001 7 6 1698 1705
PHOX2B is a novel and specific marker for minimal residual disease testing in neuroblastoma. Journal of Clinical Oncology Stutterheim J Gerritsen A Zappeij-kannegieter L Kleijn I Dee R Hooft L et al 2008 26 33 5443 5449
Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods Livak K. J Schmittgen T. D 2001 25 4 402 408
Standardisation of operating procedures for the detection of minimal disease by QRT-PCR in children with neuroblastoma: quality assurance on behalf of SIOPEN-R-NET. European Journal of Cancer Viprey V Corrias M Kagedal B Oltra S Swerts K Vicha A et al 2007 43 2 341 350
Detection of neuroblastoma cells in bone marrow and peripheral blood by different techniques: accuracy and relationship with clinical features of patients. Clinical Cancer Research Corrias M. V Faulkner L. B Pistorio A Rosanda C Callea F Piccolo M. S et al 2004 10 23 7978 7985
Potential application of ELAVL4 real-time quantitative reverse transcription-PCR for detection of disseminated neuroblastoma cells. Clinical Chemistry Swerts K De Moerloose B Dhooge C Vandesompele J Hoyoux C Beiske K et al 2006 52 3 438 445
Detection of microscopic disease: comparing histology, immunocytology, and RT-PCR of tyrosine hydroxylase, GAGE, and MAGE. Medical Pediatric Oncology Cheung I. Y Cheung N. K 2001 36 1 210 212
Detection of residual neuroblastoma cells in bone marrow: comparison of flow cytometry with immunocytochemistry. Cytometry and Clinical Cytomorphology Swerts K De Moerloose B Dhooge C Brichard B Benoit Y Laureys G et al 2004 61 1 9 19
Detection of micrometastasis of neuroblastoma to bone marrow and tumor dissemination to hematopoietic autografts using flow cytometry and reverse transcriptase-polymerase chain reaction. Cancer Tsang K. S Li C. K Tsoi W. C Leung Y Shing M. M Chik K. W et al 2003 97 11 2887 2897
Detection of disseminated tumor cells in neuroblastoma: 3 log improvement in sensitivity by automatic immunofluorescence plus FISH (AIPF) analysis compared with classical bone marrow cytology. American Journal of Pathology Mehes G Luegmayr A Kornmuller R Ambros I. M Ladenstein R Gadner H et al 2003 163 2 393 399
Comparison of immunocytochemistry, real-time quantitative RT-PCR and flow cytometry for detection of minimal residual disease in neuroblastoma. International Journal of Cancer Ifversen M. R Kagedal B Christensen L. D Rechnitzer C Petersen B. L Heilmann C 2005 27 1 121 129
mRNAs of tyrosine hydroxylase and dopa decarboxylase but not of GD2 synthase are specific for neuroblastoma minimal disease and predicts outcome for children with high-risk disease when measured at diagnosis. International Journal of Cancer Trager C Vernby A Kullman A Ora I Kogner P Kagedal B 2008 123 12 2849 2855
Consensus criteria for sensitive detection of minimal neuroblastoma cells in bone marrow, blood and stem cell preparations by immunocytology and QRT-PCR: recommendations by the International Neuroblastoma Risk Group Task Force. British Journal of Cancer Beiske K Burchill S. A Cheung I. Y Hiyama E Seeger R. C Cohn S. L et al 2009 100 10 1627 1637
Exploiting gene expression profiling to identify novel minimal residual disease markers of neuroblastoma. Clinical Cancer Research Cheung I. Y Feng Y Gerald W Cheung N. K 2008 14 21 7020 7027
Minimal disease monitoring by QRT-PCR: guidelines for identification and systematic validation of molecular markers prior to evaluation in prospective clinical trials. Journal of Pathology Viprey V. F Lastowska M. A Corrias M. V Swerts K Jackson M. S Burchill S. A 2008 216 2 245 252
Favorable outcome of triploid neuroblastomas: a contribution to the special oncogenesis of neuroblastoma. Cancer Genetics and Cytogenetics Spitz R Betts D. R Simon T Boensch M Oestreich J Niggli F. K et al 2006 167 1 51 56
Biologic variables in the outcome of stages I and II neuroblastoma treated with surgery as primary therapy: a children’s cancer group study. Journal of Clinical Oncology Perez C. A Matthay K. K Atkinson J. B Seeger R. C Shimada H Haase G. M et al 2000 18 1 18 26
H, et al. Chromosomal CGH identifies patients with a higher risk of relapse in neuroblastoma without MYCN amplification. British Journal of Cancer Schleiermacher G Michon J Huon I d Enghien C. D Klijanienko J Brisse 2007 97 2 238 246
Detection of GD2-positive cells in bone marrow samples and survival of patients with localised neuroblastoma. British Journal of Cancer Corrias M. V Parodi S Haupt R Lacitignola L Negri F Sementa A. R et al 2008 98 2 263 269
Current aspects of biology, risk assessment, and treatment of neuroblastoma. Seminars in Surgical Oncology Haase G. M Perez C Atkinson J. B 1999 16 2 91 104
The biologic basis for neuroblastoma heterogeneity and risk stratification. Current Opinion in Pediatrics Maris J. M 2005 17 1 7 13
Neuroblastoma update. Current Opinion in Oncology Henry M. C Tashjian D. B Breuer C. K 2005 17 1 19 23
Multiple target molecular monitoring of bone marrow and peripheral blood samples from patients with localized neuroblastoma and healthy donors. Pediatric Blood and Cancer Corrias M. V Haupt R Carlini B Cappelli E Giardino S Tripodi G et al 2012 58 1 43 49
Quantitative analysis of tyrosine hydroxylase mRNA for sensitive detection of neuroblastoma cells in blood and bone marrow. Clinical Chemistry Trager C Kogner P Lindskog M Ponthan F Kullman A Kagedal B 2003 49 1 104 112
Pitfalls in detection of contaminating neuroblastoma cells by tyrosine hydroxylase RT-PCR due to catecholamine-producing hematopoietic cells. Anticancer Research Kuci Z Seitz G Kuci S Kreyenberg H Schumm M Lang P et al 2006A): 2075 2080
Molecular detection of dopamine decarboxylase expression by means of reverse transcriptase and polymerase chain reaction in bone marrow and peripheral blood: utility as a tumor marker for neuroblastoma. Diagnostic and Molecular Pathology Bozzi F Luksch R Collini P Gambirasio F Barzano E Polastri D et al 2004 13 3 135 143
The doublecortin gene, a new molecular marker to detect minimal residual disease in neuroblastoma. Diagnostic and Molecular Pathology Oltra S Martinez F Orellana C Grau E Fernandez J. M Canete A et al 2005 14 1 53 57
Sialyltransferase STX (ST8SiaII): a novel molecular marker of metastatic neuroblastoma. International Journal of Cancer Cheung I. Y Vickers A Cheung N. K 2006 119 1 152 156
C, et al. Prognostic value of International Neuroblastoma Pathology Classification in localized resectable peripheral neuroblastic tumors: a histopathologic study of localized neuroblastoma European Study Group 94.01 Trial and Protocol. Journal of Clinical Oncology Navarro S Amann G Beiske K Cullinane C. J d Amore E. S Gambini 2006 24 4 695 699
Treatment of localised resectable neuroblastoma. Results of the LNESG1 study by the SIOP Europe Neuroblastoma Group. British Jornal of Cancer De Bernardi B Mosseri V Rubie H Castel V Foot A Ladenstein R et al 2008 99 7 1027 1033
Detecting minimal residual disease in neuroblastoma: the superiority of a panel of real-time quantitative PCR markers. Clinical Chemistry Stutterheim J Gerritsen A Zappeij-kannegieter L Yalcin B Dee R Van Noesel M. M et al 2009 55 7 1316 1326
Tumor cell dormancy: an NCI workshop report. Cancer Biology and Therapy Vessella R. L Pantel K Mohla S 2007 6 9 1496 1504
Restricted ROC curves are useful tools to evaluate the performance of tumour markers. Statistical Methods in Medical Research Parodi S Muselli M Carlini B Fontana V Haupt R Pistoia V et al 2012Jun 26. E-pub ahead of print.
Minimal disease detection in peripheral blood and bone marrow from patients with non-metastatic neuroblastoma. Journal of Cancer Research and Clinical Oncology Yanez Y Grau E Oltra S Canete A Martinez F Orellana C et al 2011 137 8 1263 1272
Whole chromosome alterations predict survival in high-risk neuroblastoma without MYCN amplification. Clinical Cancer Research Bilke S Chen Q. R Wei J. S Khan J 2008 14 17 5540 5547
High genomic instability predicts survival in metastatic high-risk neuroblastoma. Neoplasia Stigliani S Coco S Moretti S Oberthuer A Fischer M Theissen J et al 2012 14 9 823 832
Prognostic significance of gene expression profiles of metastatic neuroblastomas lacking MYCN gene amplification. Journal of the National Cancer Institute Asgharzadeh S Pique-regi R Sposto R Wang H Yang Y Shimada H et al 2006 98 17 1193 1203
Di Cristofano C, Longo L, et al. Genome analysis and gene expression profiling of neuroblastoma and ganglioneuroblastoma reveal differences between neuroblastic and Schwannian stromal cells. Journal of Pathology Coco S Defferrari R Scaruffi P Cavazzana A 2005 207 3 346 357
Prognostic impact of gene expression-based classification for neuroblastoma. Journal of Clinical Oncology Oberthuer A Hero B Berthold F Juraeva D Faldum A Kahlert Y et al 2010 28 21 3506 3515
Differential patterns of microRNA expression in neuroblastoma are correlated with prognosis, differentiation, and apoptosis. Cancer Research Chen Y Stallings R. L 2007 67 3 976 983
Transcribed-Ultra Conserved Region expression is associated with outcome in high-risk neuroblastoma. BMC Cancer Scaruffi P Stigliani S Moretti S Coco S De Vecchi C Valdora F et al 2009
Predicting outcomes for children with neuroblastoma using a multigene-expression signature: a retrospective SIOPEN/COG/GPOH study. Lancet Oncology Vermeulen J De Preter K Naranjo A Vercruysse L Van Roy N Hellemans J et al 2009 10 7 663 671
Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes. Nature Molenaar J. J Koster J Zwijnenburg D. A Van Sluis P Valentijn L. J Van Der Ploeg I et al 2012 483 7391 589 593
A possible role for CXCR4 and its ligand, the CXC chemokine stromal cell-derived factor-1, in the development of bone marrow metastases in neuroblastoma. Journal of Immunology Geminder H Sagi-assif O Goldberg L Meshel T Rechavi G Witz I. P et al 2001 167 8 4747 4757
The tumor microenvironment: CXCR4 is associated with distinct protein expression patterns in neuroblastoma cells. Immunology Letters Nevo I Sagi-assif O Meshel T Geminder H Goldberg-bittman L Ben-menachem S et al 2004
CXCR4 expression in neuroblastoma primary tumors is associated with clinical presentation of bone and bone marrow metastases. Journal of Pediatric Surgery Russell H. V Hicks J Okcu M. F Nuchtern J. G 2004 39 10 1506 1511
CXCL12 does not attract CXCR4+ human metastatic neuroblastoma cells: clinical implications. Clinical Cancer Research Airoldi I Raffaghello L Piovan E Cocco C Carlini B Amadori A et al 2006 12 1 77 82
CXCR4 expression heterogeneity in neuroblastoma cells due to ligand-independent regulation. Molecular Cancer Carlisle A. J Lyttle C. A Carlisle R. Y Maris J. M 2009 8 126 131
Bone marrow of neuroblastoma patients shows downregulation of CXCL12 expression and presence of IFN signature. Pediatric Blood and Cancer Scaruffi P Morandi F Gallo F Stigliani S Parodi S Moretti S et al 2012 59 1 44 51
Der SDZhou A, Williams BR, Silverman RH. Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays. Proceeding National Academy of Science USA 1998 95 26 15623 15628
How cells respond to interferons. Annual Review of Biochemistry Stark G. R Kerr I. M Williams B. R Silverman R. H Schreiber R. D 1998 67 227 264
Neoplastic progression in melanoma and colon cancer is associated with increased expression and activity of the interferon-inducible protein kinase, PKR. Oncogene Kim S. H Gunnery S Choe J. K Mathews M. B 2002 21 57 8741 8748
Tumor immunobiological differences in prostate cancer between African-American and European-American men. Cancer Research Wallace T. A Prueitt R. L Yi M Howe T. M Gillespie J. W Yfantis H. G et al 2008 68 3 927 936
Differences in the tumor microenvironment between African-American and European-American breast cancer patients. Plos One Martin D. N Boersma B. J Yi M Reimers M Howe T. M Yfantis H. G et al 2009e4531.
ISG20, an actor of the innate immune response. Biochimie Degols G Eldin P Mechti N 2007
A novel unsupervised method to identify genes important in the anti-viral response: application to interferon/ribavirin in hepatitis C patients. Plos One Brodsky L. I Wahed A. S Li J Tavis J. E Tsukahara T Taylor M. W 2007e584.
STAT1 is overexpressed in tumors selected for radioresistance and confers protection from radiation in transduced sensitive cells. Proceeding National Academy of Science USA Khodarev N. N Beckett M Labay E Darga T Roizman B Weichselbaum R. R 2004 101 6 1714 1719
Infection, immunoregulation, and cancer. Immunology Reviews Rook G. A Dalgleish A 2011 240 1 141 159
Haematopoietic stem cell release is regulated by circadian oscillations. Nature Mendez-ferrer S Lucas D Battista M Frenette P. S 2008 452 7186 442 447
Occurrence of two types of secretory vesicles in the human neuroblastoma SH-SY5Y. Journal of Neurochemistry Goodall A. R Danks K Walker J. H Ball S. G Vaughan P. F 1997 68 4 1542 1552
The chemokine receptor CXCR4 strongly promotes neuroblastoma primary tumour and metastatic growth, but not invasion. Plos One Meier R Muhlethaler-mottet A Flahaut M Coulon A Fusco C Louache F et al 2007e1016.
Neuroblastoma cells isolated from bone marrow metastases contain a naturally enriched tumor-initiating cell. Cancer Research Hansford L. M Mckee A. E Zhang L George R. E Gerstle J. T Thorner P. S et al 2007 67 23 11234 11243
System-level analysis of neuroblastoma tumor-initiating cells implicates AURKB as a novel drug target for neuroblastoma. Clinical Cancer Research Morozova O Vojvodic M Grinshtein N Hansford L. M Blakely K. M Maslova A et al 2010 16 18 4572 4582
Tumor-initiating cells in childhood neuroblastoma--letter. Cancer Research Mohlin S Pietras A Wigerup C Ora I Andang M Nilsson K et al 2012 72 3 821 2author reply 3.
Functional sphere profiling reveals the complexity of neuroblastoma tumor-initiating cell model. Neoplasia Coulon A Flahaut M Muhlethaler-mottet A Meier R Liberman J Balmas-bourloud K et al 2011 13 10 991 1004
Expression of costimulatory molecules in human neuroblastoma. Evidence that CD40+ neuroblastoma cells undergo apoptosis following interaction with CD40L. British Journal of Cancer Airoldi I Lualdi S Bruno S Raffaghello L Occhino M Gambini C et al 2003 88 10 1527 1536
Natural killer cell-mediated killing of freshly isolated neuroblastoma cells: critical role of DNAX accessory molecule-1-poliovirus receptor interaction. Cancer Research Castriconi R Dondero A Corrias M. V Lanino E Pende D Moretta L et al 2004 64 24 9180 9184
Bone marrow-infiltrating human neuroblastoma cells express high levels of calprotectin and HLA-G proteins. Plos One. Morandi F Scaruffi P Gallo F Stigliani S Moretti S Bonassi S et al 2012e29922.
Human bone marrow mesenchymal stromal cells express the neural ganglioside GD2: a novel surface marker for the identification of MSCs. Blood Martinez C Hofmann T. J Marino R Dominici M Horwitz E. M 2007 109 10 4245 4248
Differential roles of Trk and Bassili M Birman E Schor N. F Saragovi H. U 75neurotrophin receptors in tumorigenesis and chemoresistance ex vivo and in vivo. Cancer Chemotherapy and Pharmacology. 2010
Identification of 4Ig-B7-H3 as a neuroblastoma-associated molecule that exerts a protective role from an NK cell-mediated lysis. Proceeding National Academy of Science USA Castriconi R Dondero A Augugliaro R Cantoni C Carnemolla B Sementa A. R et al 2004 101 34 12640 12645
S100A8/A9 at low concentration promotes tumor cell growth via RAGE ligation and MAP kinase-dependent pathway. Journal of Leukocyte Biology Ghavami S Rashedi I Dattilo B. M Eshraghi M Chazin W. J Hashemi M et al 2008 83 6 1484 1492
Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock. Nature Medicine Vogl T Tenbrock K Ludwig S Leukert N Ehrhardt C Van Zoelen M. A et al 2007 13 9 1042 1049
LeMaoult J, Carosella ED. Expression of tolerogenic HLA-G molecules in cancer prevents antitumor responses. Seminars in Cancer Biology Rouas-freiss N Moreau P Menier C 2007 17 6 413 421
Human neuroblastoma cells trigger an immunosuppressive program in monocytes by stimulating soluble HLA-G release. Cancer Research Morandi F Levreri I Bocca P Galleni B Raffaghello L Ferrone S et al 2007 67 13 6433 6441